Tectonic Therapeutic reports favorable Phase 1 safety, tolerability and PK for TX2100 in HHT
Tectonic Therapeutic (TECX) announced favorable Phase 1 safety, tolerability and pharmacokinetic (PK) results for TX2100, a novel approach for the treatment of hereditary hemorrhagic telangiectasia (HHT).